Cambrex Corporation, a life sciences company, provides various products and services for the development and commercialization of new and generic therapeutics worldwide.
Moderate growth potential with mediocre balance sheet.
Share Price & News
How has Cambrex's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: CBM has not had significant price volatility in the past 3 months.
7 Day Return
US Life Sciences
1 Year Return
US Life Sciences
Return vs Industry: CBM exceeded the US Life Sciences industry which returned 29.7% over the past year.
Return vs Market: CBM exceeded the US Market which returned 24.7% over the past year.
Price Volatility Vs. Market
How volatile is Cambrex's share price compared to the market and industry in the last 5 years?
Simply Wall St News
7 months ago | Simply Wall StDid Cambrex Corporation (NYSE:CBM) Insiders Sell Shares?
8 months ago | Simply Wall StIs Cambrex's (NYSE:CBM) 105% Share Price Increase Well Justified?
8 months ago | Simply Wall StCambrex (NYSE:CBM) Has A Somewhat Strained Balance Sheet
Is Cambrex undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: CBM ($59.99) is trading above our estimate of fair value ($42.12)
Significantly Below Fair Value: CBM is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: CBM is poor value based on its PE Ratio (56.3x) compared to the Life Sciences industry average (37.4x).
PE vs Market: CBM is poor value based on its PE Ratio (56.3x) compared to the US market (18.9x).
Price to Earnings Growth Ratio
PEG Ratio: CBM is poor value based on its PEG Ratio (2.4x)
Price to Book Ratio
PB vs Industry: CBM is good value based on its PB Ratio (3x) compared to the US Life Sciences industry average (5.3x).
How is Cambrex forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CBM's forecast earnings growth (23.6% per year) is above the savings rate (1.7%).
Earnings vs Market: CBM's earnings (23.6% per year) are forecast to grow faster than the US market (14.3% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: CBM's revenue (4.8% per year) is forecast to grow slower than the US market (7.5% per year).
High Growth Revenue: CBM's revenue (4.8% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if CBM's Return on Equity is forecast to be high in 3 years time
How has Cambrex performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: CBM has high quality earnings.
Growing Profit Margin: CBM's current net profit margins (5.8%) are lower than last year (22.8%).
Past Earnings Growth Analysis
Earnings Trend: CBM's earnings have grown by 8.7% per year over the past 5 years.
Accelerating Growth: CBM's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: CBM had negative earnings growth (-72.9%) over the past year, making it difficult to compare to the Life Sciences industry average (34.6%).
Return on Equity
High ROE: CBM's Return on Equity (5.3%) is considered low.
How is Cambrex's financial position?
Financial Position Analysis
Short Term Liabilities: CBM's short term assets ($405.9M) exceed its short term liabilities ($171.1M).
Long Term Liabilities: CBM's short term assets ($405.9M) do not cover its long term liabilities ($659.6M).
Debt to Equity History and Analysis
Debt Level: CBM's debt to equity ratio (74%) is considered high.
Reducing Debt: CBM's debt to equity ratio has increased from 26% to 74% over the past 5 years.
Debt Coverage: CBM's debt is well covered by operating cash flow (26.1%).
Interest Coverage: CBM's interest payments on its debt are well covered by EBIT (5.1x coverage).
Inventory Level: CBM has a high level of physical assets or inventory.
Debt Coverage by Assets: CBM's debt is not covered by short term assets (assets are 0.8x debt).
What is Cambrex's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate CBM's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate CBM's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if CBM's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CBM's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: CBM is not paying a notable dividend for the US market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of CBM's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Steve Klosk (62yo)
Mr. Steven M. Klosk, also known as Steve, has been the Chief Executive Officer and President at Cambrex Corporation and its subsidiary, Zenara Pharma Limited since May 14, 2008. Mr. Klosk has over 14 years ...
CEO Compensation Analysis
Compensation vs Market: Steve's total compensation ($USD4.01M) is about average for companies of similar size in the US market ($USD3.86M).
Compensation vs Earnings: Steve's compensation has been consistent with company performance over the past year.
|Executive VP of Corporate Development & Strategy and CFO||1.25yrs||US$2.91m||0.078% $1.6m|
|Executive VP & COO||8.92yrs||US$3.29m||0.074% $1.5m|
|Senior VP||4.83yrs||US$1.34m||no data|
|Director of Marketing & Communications||no data||no data||no data|
|Senior VP & Chief Human Resources Officer||0.50yr||no data||no data|
|President of Drug Products||0.50yr||no data||no data|
|President of Drug Substance||0.50yr||no data||no data|
|President of CDMO Sales & Marketing||0.50yr||no data||no data|
|VP & Corporate Controller||14.25yrs||no data||no data|
Experienced Management: CBM's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.
|Independent Director||3.75yrs||US$196.00k||0.018% $369.6k|
|Independent Director||25.92yrs||US$196.00k||0.18% $3.7m|
|Independent Director||36.92yrs||US$212.00k||0.12% $2.4m|
|Independent Director||3.17yrs||US$185.00k||0.015% $305.5k|
|Non-Executive Chairman||5.67yrs||US$360.00k||0.046% $929.0k|
|Independent Director||2.17yrs||US$39.41k||0.012% $234.5k|
|Independent Director||4.08yrs||US$196.00k||0.014% $290.5k|
Experienced Board: CBM's board of directors are considered experienced (4.9 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Cambrex Corporation's company bio, employee growth, exchange listings and data sources
- Name: Cambrex Corporation
- Ticker: CBM
- Exchange: NYSE
- Founded: 1981
- Industry: Life Sciences Tools and Services
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$2.023b
- Shares outstanding: 33.72m
- Website: https://www.cambrex.com
Number of Employees
- Cambrex Corporation
- One Meadowlands Plaza
- East Rutherford
- New Jersey
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|CBM||NYSE (New York Stock Exchange)||Yes||Common Stock||US||USD||Sep 1987|
|XBX||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Sep 1987|
Cambrex Corporation, a life sciences company, provides various products and services for the development and commercialization of new and generic therapeutics worldwide. Its products comprise active pharmaceutical ingredients and pharmaceutical intermediates that are used in the production of prescription and over-the-counter drug products, as well as finished dosage forms. The company serves generic drug companies; and companies that discover and commercialize small molecule human therapeutics. The company sells its products directly, as well as through independent agents. Cambrex Corporation was founded in 1981 and is headquartered in East Rutherford, New Jersey.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2019/12/08 23:33|
|End of Day Share Price||2019/12/03 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.